InvestorsHub Logo
Followers 497
Posts 30965
Boards Moderated 0
Alias Born 01/31/2008

Re: stocks2watch post# 564

Wednesday, 07/11/2018 10:24:21 AM

Wednesday, July 11, 2018 10:24:21 AM

Post# of 26809
AngioSoma, Inc. (OTC: SOAN) is in discussions to engage a respected pharmaceutical regulatory advisory firm to help it navigate the Food and Drug Administration’s (FDA) third and last step in the approval process. If the biologic – named LiprostinTM – gets the FDA’s nod, it would then become the flagship product of AngioSoma, Inc.
https://www.otcmarkets.com/stock/SOAN/news/story?e&id=1113673

All posts are my opinion and are not recommendations to buy or sell

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GSTC News